Daily Archives: February 18, 2016

Gionee to Launch S8 and Introduce a New Era of Video Shooting

BARCELONA, Spain, Feb. 18, 2016 /PRNewswire — Gionee, a global telecommunications solutions provider, will officially launch its new smartphone S8 at Mobile World Congress (MWC) 2016. The phone will open up a new era of mobile video shooting and photography.

Gionee has started to produce phones since 2002 and owned the longest history among those brands in China. It understands keeping the pace with global industry development and fulfilling consumer needs are keys to success. Last year, Gionee successfully launched S7 at MWC, and media was positive to the slim design. “Unlike other similar products, it has not only a slim body, but also owns comfortable experience.”

Gionee also has been a recognized leader on super power. In 2015, Gionee launched M5 plus with the battery which can last for 3 days, solving the constant recharging issue. Moreover, the body’s visual thickness is just 3.5mm, providing users more comfortable hand held experience.

Being a leading phone manufacturer in China, how to continuously evolve and to globalize are the urgent questions. William Lu, president of Gionee, is happy to share his thoughts. Come and join us at Theatre C Hall 8 @ MWC on February 22, 2pm to learn more and share the joy!

Visitors can also visit our booth #C61 in Hall 7.

About Gionee

Established in September 2002, Gionee Communication Equipment Co. Ltd. devotes to develop innovative cellular mobile devices to users who values global connection. The company is now the world’s top 10 mobile manufacturer and its handsets ship to over 50 countries. For more information about Gionee, please visit global.gionee.com.

Website:http://global.gionee.com/news_detail.php?id=31&c=1

Johnson & Johnson lance un appel aux idées innovantes afin de réduire les infections au VIH en Afrique subsaharienne

Les partenaires DREAMS annoncent un défi de l’innovation de 85 millions $ axé sur les solutions pour les adolescentes et les jeunes femmes

NEW BRUNSWICK, New Jersey, le 18 février 2016 /PRNewswire/ — Aujourd’hui, Johnson & Johnson (NYSE : JNJ) a lancé un appel pour des idées innovantes dans le cadre du défi de l’innovation DREAMS qui est soutenu par le Plan d’urgence du Président des États-Unis pour la lutte contre le SIDA (PEPFAR – U.S. President’s Emergency Plan for AIDS Relief), Janssen Pharmaceutica, NV, l’une des sociétés pharmaceutiques Janssen de Johnson & Johnson, et ViiV Healthcare. Les propositions d’innovations révolutionnaires permettant de réduire les infections au VIH chez les adolescentes et les jeunes femmes dans dix pays subsahariens sont actuellement acceptées. La date limite de soumission pour être récompensé est fixée au 28 mars 2016.

Johnson & Johnson issued a call for innovative ideas to reduce HIV infections in adolescent girls and young women in sub-Saharan Africa as part of the DREAMS Innovation Challenge, sponsored by Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and ViiV Healthcare.

Photo – http://photos.prnewswire.com/prnh/20160216/333964

Au total, 85 millions $ seront remis pour récompenser les solutions durables innovantes dans six domaines prioritaires du défi qui donneront aux jeunes femmes la possibilité de vivre la vie déterminée, résiliente, responsabilisée, exempte de SIDA, encadrée et sûre (Determined, Resilient, Empowered, AIDS-Free, Mentored, and Safe, DREAMS soit RÊVES en français) qu’elles méritent. Les solutions gagnantes devront faire preuve d’un état de préparation adéquat pour être rapidement mises en œuvre dans un ou plusieurs des dix pays DREAMS et les effets devront être visibles dans un délai de deux ans, avec des perspectives de changement à long terme.

« Nous croyons que les innovations révolutionnaires nécessaires pour réduire les infections au VIH chez les adolescentes et les jeunes femmes peuvent venir de n’importe où dans le monde », a déclaré Paul Stoffels, M.D., conseiller scientifique en chef et président mondial, pharmaceutique, Johnson & Johnson. « Notre espoir en soutenant le défi de l’innovation DREAMS est de générer de nouvelles idées afin de nous aider à atteindre d’ici la fin de l’année 2017 une baisse de 40 pour cent des infections au VIH chez les adolescentes et les jeunes femmes vivant dans dix pays subsahariens ».

Le SIDA est la principale cause de mortalité chez les femmes en âge de procréer dans les pays à revenu faible ou à revenu intermédiaire. Les adolescentes et jeunes femmes représentent 380 000 nouvelles infections par an, soit plus de 7 000 nouvelles infections par semaine globalement.

« Alors que nous avons réalisé des progrès considérables dans la réponse mondiale au VIH/SIDA, les adolescentes et jeunes femmes ont été largement oubliées », a déclaré l’ambassadrice Deborah L. Birx, coordonnatrice de la lutte mondiale contre le SIDA des États-Unis et représentante spéciale aux États-Unis pour la diplomatie en matière de santé mondiale. « Avec les filles et jeunes femmes comptant pour près de 71 pour cent de l’ensemble des nouvelles infections au VIH parmi les adolescents en Afrique subsaharienne, nous avons un besoin urgent de solutions innovantes qui les responsabilisent afin de préserver leur santé et leur permettre de poursuivre leurs rêves ».

« Une nouvelle réflexion et des approches à fort impact sont nécessaires pour s’attaquer aux nombreuses complexités à l’origine de cette crise mondiale », a déclaré Jaak Peeters, responsable de l’organisation pour la santé publique mondiale de Johnson & Johnson. « En nous attaquant aux facteurs et à la complexité qui affectent ces jeunes femmes à un niveau fondamental, nous espérons améliorer de manière quantifiable la situation sanitaire et créer un changement pérenne. Ce sont des composantes importantes de l’approche de Johnson & Johnson pour améliorer la santé publique mondiale ».

Johnson & Johnson, par le biais de ses sociétés pharmaceutiques Janssen, a rejoint le partenariat DREAMS en tant que partenaire de référence en décembre dernier. Le partenariat ambitieux d’un montant de 385 millions $ apporte un ensemble essentiel d’approches fondées sur des données probantes qui vont au-delà du secteur de la santé et s’attaquent aux facteurs structurels qui augmentent directement ou indirectement les risques pour les jeunes filles de contracter le VIH, et notamment la pauvreté, l’inégalité des sexes, les violences sexuelles et le manque d’éducation. Le partenariat DREAMS inclut également PEPFAR, la fondation Bill & Melinda Gates, Girl Effect, Gilead Sciences, et ViiV Healthcare.

Produire un impact durable dans la santé publique globale

Combattre le VIH est une composante essentielle de la longue tradition de Johnson & Johnson en matière d’engagement et de partenariat pour améliorer la santé publique globale des personnes, familles et communautés du monde entier. Par le biais de son organisation pour la santé publique, la société vise à apporter des solutions fondées sur des données probantes intégrées pour répondre de manière complète aux besoins en matière de santé et produire un impact significatif et pérenne dans trois domaines prioritaires essentiels : le VIH, la santé maternelle et infantile et la tuberculose ultrarésistante (TB-UR) et multirésistante (TB-MR).

Informations concernant les candidatures pour le défi de l’innovation DREAMS

Le partenariat DREAMS prévoit d’annoncer les vainqueurs à la mi-juillet, suivi par la mise en œuvre au début de l’automne 2016. Les prix pour les défis iront de 100 000 $ à 40 millions $. Les solutions recherchées seront mises en œuvre au Kenya, au Lesotho, au Malawi, en Mozambique, en Afrique du Sud, au Swaziland, en Tanzanie, en Ouganda, en Zambie et au Zimbabwe.

Les candidats doivent soumettre une expression d’intérêt (EOI) sur le site Web du défi : www.dreamschallenge.org avant le 28 mars 2016 à 23 h 59 heure avancée de l’Est (HAE). Les candidatures seront examinées et les finalistes seront invités à soumettre une candidature.

Pour obtenir davantage d’informations sur le défi ou pour présenter votre candidature, visitez le site Web du défi de l’innovation DREAMS, www.dreamschallenge.org. Les candidats intéressés peuvent télécharger l’annonce de possibilité du défi pour obtenir des informations détaillées concernant les exigences en matière de candidature, ainsi que les conditions.

À propos de Johnson & Johnson

Prendre soin de chacun, individuellement : voilà ce qui inspire et unit les salariés de Johnson & Johnson. Nous soutenons la recherche et la science en proposant des idées, produits et services innovants dans le but d’améliorer la santé et le bien-être de tous. Notre société, qui emploie quelque 128 000 personnes dans plus de 265 sociétés exploitantes Johnson & Johnson, collabore avec des partenaires dans le domaine de la santé. Nos activités profitent quotidiennement à plus d’un milliard de personnes à travers le monde.

Top Security – ComScire Launches Small Footprint Quantum Random Number Generator

GAINESVILLE, FL–(Marketwired – Feb 18, 2016) –  The Quantum World Corporation – ComScire® announces immediate availability of its small footprint Pure Quantum™ random number generators (QRNGs). The two models, PQ4000KS and PQ4000KSI, are fully compatible with Model PQ4000KU application software. The PQ4000KS is one-third the size of the PQ4000KU, with a footprint of 80 mm by 54 mm. The PQ4000KSI has a footprint of 63.5 mm by 50 mm for mounting within the computer enclosure if additional physical security is required.

Both generators are functionally identical to the PQ4000KU (4 Mbps), and are designed to meet NIST SP 800-90 B and C Draft Recommendations for Random Bit Generator Constructions. Features include hardware startup and continuous runtime testing with failsafe shutdown, internal raw data streams available for testing, redundant generators for highest reliability, and independent power regulation for generator circuits. Model PQ4000KS is housed in an Aluminum enclosure for electromagnetic shielding against radiated or received electromagnetic fields. Our White Paper provides in-depth descriptions of the theory, construction and calculated entropy levels for the new generators, and illustrates the effectively perfect statistical properties of the output numbers which require no post processing.

Used for gaming, cryptography, random selections and drawings, key generation, Monte Carlo simulation and scientific research. USB connected, Bus powered and easy-to-use ActiveX interface. Program examples and full driver software available for download. Every Pure Quantum generator is Guaranteed to Pass Any Test for Randomness™. Quantity and reseller discounts available. Custom design for large volume applications. ComScire – Confidence and Security worldwide for over 20 years.

The Quantum World Corporation
Email Email Contact
Phone (352) 334-7299

Johnson & Johnson Issues Call for Innovative Ideas to Reduce HIV Infections in Sub-Saharan Africa

DREAMS Partners Announce $85 Million Innovation Challenge Focused on Solutions for Adolescent Girls and Young Women

NEW BRUNSWICK, New Jersey, Feb. 17, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today issued a call for innovative ideas as part of the DREAMS Innovation Challenge, which is supported by the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and ViiV Healthcare. Proposals are currently being accepted for breakthrough innovations to reduce HIV infections in adolescent girls and young women in 10 sub-Saharan African countries. The submission deadline to be considered for an award is March 28, 2016.

Johnson & Johnson issued a call for innovative ideas to reduce HIV infections in adolescent girls and young women in sub-Saharan Africa as part of the DREAMS Innovation Challenge, sponsored by Janssen Pharmaceutica, NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and ViiV Healthcare.

Photo – http://photos.prnewswire.com/prnh/20160216/333964

A total of $85 million will be awarded for innovative, sustainable solutions to six Challenge Focus Areas that will give young women the opportunity to live the Determined, Resilient, Empowered, AIDS-Free, Mentored, and Safe lives they deserve. Winning solutions must demonstrate readiness for rapid implementation in one or more of the 10 DREAMS countries and ability to show impact within two years with potential for long-lasting change.

“We believe that breakthrough innovations needed to reduce the HIV infections in adolescent girls and young women can come from anywhere in the world,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. “Our hope in supporting the DREAMS Innovation Challenge is to unleash new ideas to help us achieve by the end of 2017, 40 percent reduction in HIV infections among adolescent girls and young women living in 10 sub-Saharan countries.”

AIDS is the leading cause of death among women of reproductive age in low- and middle-income countries. Adolescent girls and young women account for 380,000 new infections a year or more than 7,000 new infections a week globally.

“While we have made considerable progress in the global response to HIV/AIDS, adolescent girls and young women have been largely left behind,” said Ambassador Deborah L. Birx, U.S. Global AIDS Coordinator and U.S. Special Representative for Global Health Diplomacy. “With girls and young women accounting for 71 percent of all new HIV infections among adolescents in sub-Saharan Africa, we urgently need innovative solutions that empower them to protect their health and pursue their dreams.”

“New thinking and high-impact approaches are needed to address the many complexities that drive this urgent health crisis,” said Jaak Peeters, head of Johnson & Johnson’s Global Public Health organization. “By addressing the factors and complexities that impact these young women at a fundamental level, we hope to measurably improve health outcomes and create enduring change. These are important components of Johnson & Johnson’s approach to improving global public health.”

Johnson & Johnson, through its Janssen Pharmaceutical Companies, joined the DREAMS Partnership as an anchor partner last December. The ambitious $385 million partnership delivers a Core Package of evidence-informed approaches that go beyond the health sector, addressing the structural drivers that directly or indirectly increase girls’ HIV risk, including poverty, gender inequality, sexual violence, and lack of education. The DREAMS Partnership also includes PEPFAR, the Bill & Melinda Gates Foundation, Girl Effect, Gilead Sciences, and ViiV Healthcare.

Delivering Sustainable Impact in Global Public Health

Combatting HIV is an important component of Johnson & Johnson’s long-standing legacy of commitment and partnership to improve global public health for individuals, families and communities worldwide. Through its global public health organization, the company aims to deliver integrated evidence-based solutions to address comprehensive health needs and deliver meaningful and enduring impact in three core focus areas: HIV, maternal and child health, and extensively drug-resistant (XDR)- and Multidrug-resistant (MDR)- tuberculosis (TB).

DREAMS Innovation Challenge Application Information

The DREAMS Partnership expects to announce the winners in mid-July followed by implementation in early fall 2016. Challenge awards will range from $100,000 to $40 million. Solutions are sought for implementation in Kenya, Lesotho, Malawi, Mozambique, South Africa, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.

Applicants must submit an Expression of Interest (EOI) on the Challenge website: www.dreamschallenge.org by March 28, 2016 at 11:59 PM Eastern Daylight Time (EDT). Submissions will be reviewed, and finalists will be invited to submit an Application.

For more information about the Challenge or to apply, visit the DREAMS Innovation Challenge website, www.dreamschallenge.org. Interested applicants may download the Challenge Opportunity Announcement for full details about application requirements and terms and conditions.

About Johnson & Johnson

Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 128,000 employees at more than 265 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

<title> Mozambique banana fungus poses threat to SA plantations</title>

A serious outbreak of a fungal disease which has been responsible for decimating millions of hectares of banana plantations across the world, could now pose a threat to South Africa’s R1.5 billion banana industry.

Panama Disease has been present in plantations in north-eastern Mozambique’s Nampula province for the past two years.

According to Altus Viljoen, a pre-eminent plant pathologist from the University of Stellenbosch, the outbreak is spreading rapidly across the Metocheria Farm, a 3 000 hectare farm owned by Norwegian company Norfund.

The outbreak at Metocheria is very serious. With the flooding at the beginning of 2015 the fungus has been spread almost everywhere on the farm, and most likely also down the Monapo River, said Viljoen.

Viljoen said that the disease could spread to more banana plantations in the Nampula province and then into Africa, where it may threaten food security.

The outbreak in northern Mozambique most certainly poses a risk to all its neighbouring countries. A major means of spread is water, as well as planting material and soil attached to shoes and vehicles from the farm. South Africans had been visiting the affected farms in Mozambique in the past, and are still visiting the farm to do business. If proper biosecurity is not introduced, South African growers might be affected, Viljoen explained.

According to the Agriculture, Forestry and Fisheries, bananas contribute more than 50% of the total gross value of subtropical fruits in South Africa, amounting to around R1.5 billion.

Panama Disease, which is caused by the Fusarium fungus, is a soil pathogen which infects the root system and goes on to colonise the entire plant.

In the 1950s, the disease wiped out almost all of the banana plantations in Central and South America. Despite growers switching to a new banana variety called the Cavendish, a new strain of the disease appeared in the 1990s, affecting large areas of South East Asia and spreading to northern Australia.

In Mozambique, a collaborative group of scientists is assisting the affected farms with research and information on how to deal with the outbreaks.

However, Viljoen said that he is surprised at how little is being done by the Banana Growers’ Association of South Africa (BGASA) to protect South Africa’s industry from the disease.

I have been invited everywhere in the world to help people protect the industry, but BGASA has not met with me to develop a biosecurity strategy for the country, he said.

BGASA chairman, Kobus Lourens, responded by saying that the chances of South Africa getting the disease were slim.

Yes, there is a chance of it spreading to South Africa, because if it got to Mozambique it can get anywhere. But to put it in perspective the site is 2 500km from us. It could be brought to South Africa by someone that takes plant material or soil, but it would have to be intentional, said Lourens.

Lourens added that Viljoen may be undervaluing the efforts BGASA has put into strategies to control the disease.

I have met with more than one plant protection officer in South Africa and they are well aware of the outbreak. The Department of Agriculture does have security measures in place, but only when we have an outbreak here or closer to us the measures will kick in. Nothing will be done while the disease is still in northern Mozambique, Lourens said.

Joyce Mkhonto (53) a fruit seller in Mbombela, said that bananas are her best-selling product.

If there is a disease it means I won’t be able to sell bananas anymore. It will have a heavy effect on my business, Mkhonto said.